Abstract |
We report a 1-year-old boy with infantile lymphoblastic leukemia in first complete remission who received a cord blood stem cell transplantation (CBSCT) from an HLA identical sibling. We collected 120 ml of cord blood when his brother was born, which contained 4.2 x 10(8) mononuclear cells (4.2 x 10(7)/kg) and 3.1 x 10(5) CFU-GM (3.1 x 10(4)/kg). One month prior to transplantation, he showed persistent fever and liver dysfunction, and was finally diagnosed as having primary cytomegalovirus (CMV) infection which was demonstrated by elevation of serum anti-CMV- IgM. The administration of ganciclovir dramatically improved the clinical symptoms and abnormal laboratory findings, and was continued up to 1 month after transplantation to suppress the CMV reactivation. The preconditioning regimen consisted of busulfan (16 mg/kg/4 days) and cyclophosphamide (120 mg/kg/2 days), and cyclosporin A (CyA) alone was used for graft-versus-host disease (GVHD) prophylaxis. Fever suspicious of grade I GVHD developed on day 19, but subsided by increasing the dose of CyA. The WBC and platelet counts reached greater than 1,000/microliter and 50 x 10(3)/microliter on days 12 and 42, respectively. It is now at 13 months since transplantation, and he remains in a disease free state.
|
Authors | K Goi, K Sugita, N Miyamoto, N Karakida, M Nakamura, S Kojika, K Iijima, K Kagami, S Nakazawa |
Journal | [Rinsho ketsueki] The Japanese journal of clinical hematology
(Rinsho Ketsueki)
Vol. 38
Issue 11
Pg. 1229-33
(Nov 1997)
ISSN: 0485-1439 [Print] Japan |
PMID | 9423343
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Antiviral Agents
- Ganciclovir
|
Topics |
- Antiviral Agents
(therapeutic use)
- Cytomegalovirus Infections
(drug therapy, etiology)
- Fetal Blood
(cytology)
- Ganciclovir
(therapeutic use)
- Hematopoietic Stem Cell Transplantation
- Humans
- Infant
- Male
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(therapy)
|